Diagnosis and Management of Allograft Failure

Clinics in Liver Disease

Volumn 10, Issue 2, 2006, Pages 407-435

  Burton Jr , James R ^a   Rosen, Hugo R ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ANTIVIRUS AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; ENTECAVIR; HEPATITIS B ANTIBODY; IMMUNOSUPPRESSIVE AGENT; LAMIVUDINE; NUCLEOSIDE ANALOG; OKT 3; TACROLIMUS;

ACUTE CELLULAR REJECTION; ARTERY THROMBOSIS; AUTOIMMUNE HEPATITIS; CHRONIC GRAFT REJECTION; GRAFT FAILURE; HEPATITIS B; HEPATITIS C; HUMAN; HYPERACUTE GRAFT REJECTION; LIVER ARTERY THROMBOSIS; LIVER TOXICITY; LIVER TRANSPLANTATION; LIVER VEIN THROMBOSIS; PORTAL VEIN THROMBOSIS; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PROGNOSIS; REVIEW; RISK FACTOR;

GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; LIVER DISEASES; LIVER TRANSPLANTATION; RECURRENCE; REPERFUSION INJURY;

EID: 33846187744     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2006.05.003     Document Type: Review

References (148)

1. Neuberger J. Chronic allograft dysfunction: diagnosis and management. Is it always progressive?. Liver Transpl 11 (2005) S63-S68
2. Villamil F.G., and Zingale F.G. Graft dysfunction. In: O'Grady J.G., Lake J.R., and Howdle P.D. (Eds). Comprehensive clinical hepatology. 1st edition (2000), Mosby, London 39.1-39.17
3. Rosen H.R., Martin P., Goss J., et al. Significance of early aminotransferase elevation after liver transplantation. Transplantation 65 (1998) 68-72
4. Ploeg R.J., D'Alessandro A.M., Knechtle S.J., et al. Risk factors for primary dysfunction after liver transplantation-a multivariate analysis. Transplantation 55 (1993) 807-813
5. Furukawa H., Todo S., Imventarza O., et al. Effect on cold ischemia time on the early outcome of human hepatic allografts persevered with UW solution. Transplantation 51 (1991) 1000-1004
6. Oh C.-K., Sawyer R.G., Pelletier S.J., et al. Independent predictors for primary non-function after liver transplantation. Yonsei Med J 45 (2004) 1155-1161
7. Imber C.J., St. Peter S.D., Handa A., et al. Hepatic steatosis and its relationship to transplantation. Liver Transpl 8 (2002) 415-423
8. Greig P.D., Woolf G.M., Sinclair S.B., et al. Treatment of primary liver graft nonfunction with prostaglandin E1. Transplantation 48 (1989) 447-453
9. Briegel J., Haller M., Zulke C., et al. Primary grafter nonfunction following orthotopic liver transplantation: treatment with prostacyclin. Transplant Proc 24 (1992) 2693-2695
10. Henley K.S., Lucy M.R., Normolle D.P., et al. A double-blind, randomized, placebo-controlled trial of prostaglandin E1 in liver transplantation. Hepatology 21 (1995) 366-372
11. Stange B.J., Glanemann M., Nuessler N.C., et al. Hepatic artery thrombosis after adult liver transplantation. Liver Transpl 9 (2003) 612-620
12. Mazzaferro Z., Esquivel C.O., Makowka L., et al. Hepatic artery thrombosis after pediatric liver transplantation: a medical or surgical event?. Transplantation 47 (1989) 971-977
13. Drazan K., Shaked A., Olthoff K.M., et al. Etiology and management of symptomatic adult hepatic artery thrombosis after orthotopic liver transplantation. Am Surg 62 (1996) 237-240
14. Oh C.-K., Pelletier S.J., Sawyer R.G., et al. Uni- and multivariate analysis of risk factors for early and late hepatic artier thrombosis after liver transplantation. Transplantation 71 (2001) 767-772
15. Gunsar F, Rolando N, Pastacaldi S, et al. Late hepatic artery thrombosis after orthotopic liver transplantation. Liver Transpl 2003;9:605-11.
16. Hidalgo E., Cantarell C., Charco R., et al. Risk factors for late hepatic artery thrombosis in adult liver transplantation. Transplant Proc 31 (1999) 2416-2417
17. Merion R.M., Burtch G.D., Ham J.M., et al. The hepatic arty in liver transplantation. Transplantation 48 (1989) 438-443
18. Oh C.K., Sanfey H.A., Pelletier S.J., et al. Implication of advanced donor age on the outcome of liver transplantation. Clin Transpl 14 (2000) 386-390
19. Madalosso C., de Souza Jr. N.F., Ilstrup D.M., et al. Cytomegalovirus and its association with hepatic artery thrombosis after liver transplantation. Transplantation 66 (1998) 294
20. Samuel D., Gillet D., Castaing D., et al. Portal and arterial thrombosis in liver transplantation: a frequent event in severe rejection. Transplant Proc 21 (1989) 2225-2227
21. Tanyel F.C., Ocal T., Balkanci F., et al. The factor V Leiden mutation; a possible contributor to the hepatic artery thrombosis encountered after liver transplantation in a child. J Pediatr Surg 35 (2000) 607-609
22. Schuetze S.M., and Linenberger M. Acquired proteins S deficiency with multiple thrombotic complications after orthotopic liver transplantation. Transplantation 67 (1999) 1366-1369
23. Halff G., Todo S., Tzakis A.G., et al. Liver transplantation for Budd-Chiari syndrome. Ann Surg 211 (1990) 43-49
24. Jamieson N.V., Williams R., and Calne R.Y. Liver transplantation for Budd-Chiari syndrome. Ann Chir 45 (1991) 362
25. Hemming A.W., Langer B., Greig P., et al. Treatment of Budd-Chiari syndrome with portosystemic shunt or liver transplantation. Am J Surg 171 (1996) 176
26. Srinivasan P., Rela M., Prachalias A., et al. Liver transplantation for Budd-Chiari syndrome. Transplantation 73 (2002) 973
27. Melear J.M., Goldstein R.M., Levy M.F., et al. Hematologic aspects of liver transplantation for Budd-Chiari syndrome with special reference to myeloproliferative disorders. Transplantation 74 (2002) 1090
28. Cruz E., Ascher N.L., Robers J.P., et al. High incidence of recurrence and hematologic events following liver transplantation for Budd-Chiari syndrome. Clin Transplant 19 (2005) 501-506
29. Wiesner R.H., Demetris A.J., Belle S.H., et al. Acute hepatic allograft rejection: incidence, risk factors and impact on outcome. Hepatology 28 (1998) 638-645
30. Demetris A., Batts K., Dhillon A., et al. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 25 (1997) 658-663
31. Mirza D.F., Gunson G.B., Soonawalla Z., et al. Reduced acute rejection after liver transplantation with Neoral-based triple immunosuppression. Lancet 349 (1997) 701-702
32. Neuberger J. Incidence, timing, and risk factors for acute and chronic rejection. Liver Transpl Surg 5 (1999) S30-S36
33. Anand A., Hubscher S., Gunson B., et al. Timing, significance and prognosis of late acute liver allograft rejection. Transplantation 60 (1995) 1098-1103
34. Demetris A.J., Murase N., Lee R.G., et al. Chronic rejection. A general overview of histopathology and pathophysiology with emphasis on liver, heart and intestinal allografts. Ann Transplant 2 (1997) 27-44
35. Demetris A., Adams D., Bellamy C., et al. Update of the International Banff Schema for Liver Allograft Rejection: working recommendations for the histopathologic stages and report of chronic rejection. An international panel. Hepatology 31 (2000) 792-799
36. Neil D.A.H., Adams D.H., Gunson B., et al. Is chronic rejection of liver transplants different to graft arteriosclerosis (chronic rejection) of kidney and heart transplants?. Transplant Proc 29 (1997) 2533-2534
37. Freese D.K., Snover D.C., Sharp H.L., et al. Chronic rejection after liver transplantation: a study of clinical, histopatholgical and immunological features. Hepatology 13 (1991) 882-891
38. Blakolmer K., Jain A., Ruppert K., et al. Chronic liver allograft rejection in a population treated primarily with tacrolimus as baseline immunosuppression: long-term follow-up and evaluation of features for histopathological staging. Transplantation (2000) 69-2330-6
39. Neil D.A.H., and Hubscher S.G. Histologic and biochemical changes during the evolution of chronic rejection of liver allografts. Hepatology 35 (2002) 639-651
40. Candinas D., Gunson B.K., Nightingale P., et al. Sex mismatch as a risk factor for chronic rejection of liver allografts. Lancet 346 (1995) 1117-1121
41. Blakolmer K., Seaberg E.C., Batts K., et al. Analysis of the reversibility of chronic liver allograft rejection-implications for a staging schema. Am J Surg Pathol 23 (1999) 1328-1339
42. Hayashi M., Keeffe E.B., Krams S.M., et al. Allograft rejection after liver transplantation for autoimmune liver diseases. Liver Transpl Surg 4 (1998) 208-214
43. European F.K. 506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporine in prevention of liver allograft rejection. Lancet 344 (1994) 423-428
44. Devlin J.J., O'Grady J.G., Tan K.C., et al. Ethnic variations in patient and graft survival after liver transplantation. Identification of a new risk factor for chronic allograft rejection. Transplantation 56 (1993) 1381-1384
45. Arnold J.C., Portmann B.C., O'Grady J.G., et al. Cytomegalovirus infection persists in the liver graft in the vanishing bile duct syndrome. Hepatology 16 (1992) 285-292
46. Lautenschlager I., Hockerstedt K., Jalanko H., et al. Persistent cytomegalovirus in liver allografts with chronic rejection. Hepatology 25 (1997) 190-194
47. Waldman W.J., Adams P.W., Knight D.A., et al. CMV as an exacerbating agent in transplant vascular sclerosis: potential immune-mediated mechanisms modeled in vitro. Transplant Proc 29 (1997) 1545-1546
48. Manez R., White L.T., Linden P., et al. The influence of HLA matching on cytomegalovirus hepatitis and chronic rejection after liver transplantation. Transplantation 55 (1993) 1067-1071
49. Paya C.V., Wiesner R.H., Hermans P.E., et al. Lack of association between cytomegalovirus infection, HLA matching and the vanishing bile duct syndrome after liver transplantation. Hepatology 16 (1992) 66-70
50. Sher L.S., Cosenza C.A., Michel J., et al. Efficacy of tacrolimus as rescue therapy for chronic rejection in orthotopic liver transplantation; a report of the US Multicenter Liver Study Group. Transplantation 64 (1997) 258-263
51. Reyes J., Jain A., Mazariegos G., et al. Long-term results after conversion from cyclosporine to tacrolimus in pediatric liver transplantation for acute and chronic rejection. Transplantation 69 (2000) 2573-2580
52. Forman L.M., Lewis J.D., Berlin J.A., et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 122 (2002) 889-896
53. Gane E. The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transpl 9 (2003) S28-S34
54. Berenguer M., Prieto M., Rayon J.M., et al. Natural history of clinically compensated HCV-related graft cirrhosis following liver transplantation. Hepatology 32 (2000) 852-858
55. Fattovich G., Giustina G., Degos F., et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 112 (1997) 463-472
56. Charlton M., and Wiesner R.H. Natural history and management of hepatitis C infection after liver transplantation. Semin Liver Dis 24 (2004) 79-88
57. Berenguer M., Rayon J.M., Prieto M., et al. Are posttransplantation protocol liver biopsies useful in the long term?. Liver Transpl 7 (2001) 790-796
58. Sebagh M., Rifai K., Feray C., et al. All liver recipients benefit from the protocol 10-year liver biopsies. Hepatology 37 (2003) 1293-1301
59. Pelletier S.J., Raymond D.P., Crabtree T.D., et al. Hepatitis C-induced hepatic allograft injury is associated with a pretransplantation elevated viral replication rate. Hepatology 32 (2000) 418-426
60. Charlton M., Seaberg G., Wiesner R., et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 28 (1998) 823-830
61. Sreekumar R., Gonzalez-Koch A., Moar-Kendler Y., et al. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology 32 (2000) 1125-1130
62. Sheiner P.A., Schwartz M.E., Mor E., et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 21 (1995) 30-34
63. Berenguer M., Prieto M., Cordoba J., et al. Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection. J Hepatol 28 (1998) 756-763
64. Rosen H.R., Shackleton C.R., Higa L., et al. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol 92 (1997) 1453-1457
65. Berenguer M., Crippin J., Gish R., et al. A model to predict severe HCV-related disease following liver transplantation. Hepatology 38 (2003) 34-41
66. Velidedeoglu E., Mange K.C., Frank A., et al. Factors differentially correlated with the outcome of liver transplantation in HCV+ and HCV- recipients. Transplantation 77 12 (2004) 1834-1842
67. Rosen H.R., Hinrichs D.J., Gretch D.R., et al. Association of multispecific CD4(+) response to hepatitis C and severity of recurrence after liver transplantation. Gastroenterology 117 (1999) 926-932
68. Rosen H.R., Chou S., Corless C.L., et al. Cytomegalovirus viremia: risk factor for allograft cirrhosis after liver transplantation for hepatitis C. Transplantation 64 (1997) 721-726
69. Burak K.W., Kremers W.K., Batts K.P., et al. Impact of cytomegalovirus infection, year of transplantation and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 8 (2002) 362-369
70. Bizollon T., Ahmed S.N.S., Radenne S., et al. Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence. Gut 52 (2003) 283-287
71. Biggin S.W., Beldecos A., Rabkin J.M., et al. Retransplantation for hepatic allograft failure: prognostic modeling and ethical considerations. Liver Transpl 8 (2002) 313-322
72. Todo S., Demetris A., Van Thiel D., et al. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 13 (1991) 619
73. Samuel D., Muller R., Alexander G., et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 329 (1993) 1842-1847
74. Yao F.Y., Osorio R.W., Roberts J.P., et al. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transpl 5 (1999) 491-496
75. Yoshida E.M., Erb S.R., Partovi N., et al. Liver transplantation for chronic hepatitis B infection with the use of combined lamivudine and low-dose hepatitis B immune globulin. Liver Transpl 5 (1999) 520-525
76. Angus P.W., McCaughan G.W., Gane E.J., et al. Combination low-dose hepatitis B immune globulin and lamivudine provided effective prophylaxis against post-transplantation hepatitis B. Liver Transpl 6 (2000) 429-433
77. Han S.H., Ofman J., Holt C., et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 6 (2000) 731-748
78. Marzano A., Salizzoni M., Debernardi-Venon W., et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 34 (2001) 903-910
79. Rosenau J., Bahr M.J., Tillman H.L., et al. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation: possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol 34 (2001) 895-902
80. Seehofer D., Rayes N., Naumann U., et al. Preoperative antiviral treatment and postoperative prophylaxis in HBV-DNA positive patients undergoing liver transplantation. Transplantation 72 (2001) 1381-1385
81. Schiff E.R., Lai C.L., Hadziyannis S., et al. Adefovir dipivoxil therapy for lamivudine resistant hepatitis B in pre and post liver transplantation patients. Hepatology 38 (2003) 1419-1427
82. Perrillo R.P., Hann H.W., Mutimer D., et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 126 (2004) 81-90
83. Peters M., Hann H.W., Martin P., et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 126 (2004) 91-101
84. Chang T.T., Gish R.G., Hadziyannis S.J., et al. A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients. Gastroenterology 129 (2005) 1198-1209
85. Perrillo R., Rakela J., Dienstag J., et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Hepatology 29 (1999) 1581-1586
86. Lok A.S.F. Liver transplantation for patients with lamivudine-resistant HBV: what is the optimal prophylactic strategy. Liver Transpl 11 (2005) 490-493
87. Terrault N.A., Holland C.C., Ferrell L., et al. Interferon alfa for recurrent hepatitis B infection after liver transplantation. Liver Transpl Surg 2 (1996) 132-138
88. Seehofer D., Rayes N., Neuhaus R., et al. Antiviral combination therapy for lamivudine-resistant hepatitis reinfection after liver transplantation. Transpl Int 13 Suppl 1 (2000) S359-S362
89. Polson R.J., Portmann B., Neuberger J., et al. Evidence for disease recurrence after liver transplantation for primary biliary cirrhosis. Clinical and histologic follow-up studies. Gastroenterol 97 (1989) 715-725
90. Liermann Garcia R.F., Evangelista Garcia C., McMaster P., et al. Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center. Hepatology 33 (2001) 22-27
91. Hubscher S., Elias E., Buckels J., et al. Primary biliary cirrhosis. Histological evidence of disease recurrence after liver transplantation. J Hepatol 18 (1993) 173-184
92. Sebagh M., Farges O., Dubel L., et al. Histological features predictive of recurrence of primary biliary cirrhosis after liver transplantation. Transplantation 65 (1998) 1328-1333
93. Sylvestre P.B., Batts K.P., Burgart L.J., et al. Recurrence of primary biliary cirrhosis after liver transplantation: histologic estimate of incidence and natural history. Liver Transpl 9 (2003) 1086-1093
94. Khettry U., Anand N., Faul P.N., et al. Liver transplantation for primary biliary cirrhosis: a long-term pathologic study. Liver Transpl 9 (2003) 87-96
95. Dubel L., Gorges O., Bismuth H., et al. Kinetics of anti-M2 antibodies after liver transplantation for PBC. J Hepatol 23 (1995) 674-681
96. Neuberger J., Bunson B., Hubscher S., et al. Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl 10 (2004) 488-491
97. Neuberger J. Recurrent primary biliary cirrhosis. Liver Transpl 9 (2003) 539-546
98. Guy J.E., Qian P., Lowel J.A., et al. Recurrent primary biliary cirrhosis: peritransplant factors and ursodeoxycholic acid treatment post-liver transplantation. Liver Transpl 11 (2005) 1252-1257
99. Sheng R., Zajko A.B., Campbell W.L., et al. Biliary strictures in hepatic transplants: prevalence and types in patients with primary sclerosing cholangitis vs. those with other liver diseases. AJR Am J Roentgenol 161 (1993) 297-300
100. Sheng R., Campbell W.L., Zajko A.B., et al. Cholangiographic features of biliary strictures after liver transplantation for primary sclerosing cholangitis: evidence of recurrent disease. AJR Am J Roentgenol 166 (1996) 1109-1113
101. Harrison R.F., Davies M.H., Neuberger J.M., et al. Fibrous and obliterative cholangitis in liver allografts: evidence of recurrent primary sclerosing cholangitis?. Hepatology 20 (1994) 356-361
102. Narumi S., Roberts J.P., Emond J.C., et al. Liver transplantation for sclerosing cholangitis. Hepatology 22 (1995) 451-457
103. Goss J.A., Shackleton C.R., Farmer D.G., et al. Orthotopic liver transplantation for primary sclerosing cholangitis: a 12-year single center experience. Ann Surg 225 (1997) 472-483
104. Graziadei I.W., Wiesner R.H., Batts K.P., et al. Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology 29 (1999) 1050-1056
105. Gopal D.V., Corless C.L., Rabkin J.M., et al. Graft failure from severe recurrent primary sclerosing cholangitis following orthotopic liver transplantation. J Clin Gastroenterol 37 (2003) 344-347
106. Rai R.M., Boitnott J., Klein A.S., et al. Features of recurrent primary sclerosing cholangitis in two consecutive liver allografts after liver transplantation. J Clin Gastroenterol 32 (2001) 151-154
107. Solano E., Khakhar A., Bloch M., et al. Liver transplantation for primary sclerosing cholangitis. Transplant Proc 35 (2003) 2431-4
108. Kugelmas M., Spiegelman P., Osgood M.J., et al. Different immunosuppressive regimens and recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 9 (2003) 727-732
109. Harnois D.M., Angulo P., Jorgensen R.A., et al. High-dose ursodeoxycholic acid as therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol 96 (2001) 1558-1562
110. Prados E., Cuervas-Mons V., de la Mata M., et al. Outcome of autoimmune hepatitis after liver transplantation. Transplantation 66 (1998) 1645-1650
111. Ayata G., Gordon F.D., Lewis W.D., et al. Liver transplantation for autoimmune hepatitis: a long-term pathologic study. Hepatology 32 (2000) 185-192
112. Ratziu V., Samuel D., Sebagh M., et al. Long-term follow-up after liver transplantation for autoimmune hepatitis: evidence of recurrence of primary disease. J Hepatol 30 (1999) 131-141
113. Reich D.J., Fiel I., Guarrera J.V., et al. Liver transplantation for autoimmune hepatitis. Hepatology 32 (2000) 693-700
114. Molmenti E.P., Netto G.J., Murray N.G., et al. Incidence and recurrence of autoimmune/alloimmune hepatitis in liver transplant recipients. Liver Transpl 8 (2002) 519-526
115. Renz J.F., and Ascher N.L. Liver transplantation for nonviral, nonmalignant diseases: problem of recurrence. World J Surg 26 (2002) 247-256
116. Gonzalez-Koch A., Czaja A.J., Carpenter H.A., et al. Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transpl 7 (2001) 302-310
117. Vogel A., Heinrich E., Bahr M.J., et al. Long-term outcome of liver transplantation for autoimmune hepatitis. Clin Transplant 18 (2004) 62-69
118. Alvarez F., Berg P.A., Cianchi F.B., et al. International Autoimmune Hepatitis Group report: review of criteria for diagnosing of autoimmune hepatitis. J Hepatol 31 (1999) 929-938
119. Milkiewicz P., Hubscher S.G., Skiba G., et al. Recurrence of autoimmune hepatitis after liver transplantation. Transplantation 68 (1999) 253-256
120. Wright H.L., Bou-Abboud C.F., Hassanein T., et al. Disease recurrence and rejection following liver transplantation for autoimmune chronic active liver disease. Transplantation 53 (1992) 136-139
121. Manns M.P., and Bahr J.M. Recurrent autoimmune hepatitis after liver transplantation-when non-self becomes self. Hepatology 32 (2000) 868-870
122. Neuberger J., Portmann B., Calne R., et al. Recurrence of autoimmune chronic active hepatitis following orthotopic liver grafting. Transplantation 37 (1984) 363-365
123. Birnbaum A.H., Benkov K.J., Pittman N.S., et al. Recurrence of autoimmune hepatitis in children after liver transplantation. J Pediatr Gastroenterol Nutr 25 (1997) 20-25
124. Hayashi M., Keefe E.B., Krams S.M., et al. Allograft rejection after liver transplantation for autoimmune liver disease. Liver Transpl 4 (1998) 208-214
125. Organ Procurement and Transplant Network. National Data Report. Available at: http://www.optn.org. Accessed May 30, 2005.
126. Organ Procurement and Transplantation Network: Health Resources and Service Administration (Health and Human Services) final rule, 64 Federal Register 56650-56661 (1990).
127. Biggins S.W., and Terrault N.A. Should HCV-related cirrhosis be a contraindication for retransplantation?. Liver Transpl 9 (2003) 236-238
128. Azoulay D., Linhares M.M., Huguet E., et al. Decision for retransplantation of the liver: an experience- and cost-based analysis. Ann Surg 236 (2002) 713-721
129. Rosen H.R., and Martin P. Hepatitis C infection in patients undergoing liver retransplantation. Transplantation 66 (1998) 1612-1616
130. Yoo H.Y., Maheshwari A., and Thuluvath P.J. Retransplantation of liver: primary graft nonfunction and hepatitis C virus are associated with worse outcome. Liver Transpl 9 (2003) 897-904
131. Pelletier S.J., Schaubel D.E., Punch J.D., et al. Hepatitis C is a risk factor for death after liver retransplantation. Liver Transpl 11 (2005) 434-440
132. Doyle H.R., Morelli F., McMichael J., et al. Hepatic retransplantation-an analysis of risk factors associated with outcome. Transplantation 61 (1996) 1499-1505
133. Roayaie S., Schiano T.D., Thung S.N., et al. Results of retransplantation for recurrent hepatitis C. Hepatology 38 (2003) 1428-1436
134. Ghobrial R.M., Gornbein J., Steadman R., et al. Pretransplant model to predict posttransplant survival in liver transplant patients. Ann Surg 236 (2002) 315-322
135. Wong T., Devlin J., Rolando N., et al. Clinical characteristics affecting the outcome of liver retransplantation. Transplantation 64 (1997) 878-882
136. Markmann J.F., Markowitz J.S., Yersiz H., et al. Long-term survival after retransplantation of the liver. Ann Surg 226 (1997) 408-418
137. Rosen H.R., Madden J.P., and Martin P. A model to predict survival following liver retransplantation. Hepatology 29 (1999) 365-370
138. Facciuto M., Heidt D., Guarrera J., et al. Retransplantation for late liver graft failure: predictors of mortality. Liver Transpl 6 (2000) 174-179
139. Rosen H.R., Prieto M., Casanovas-Taltavull T., et al. Validation and refinement of a survival models for liver retransplantation. Hepatology 38 (2003) 460-469
140. Yao F.Y., Saab S., Bass N.M., et al. Prediction of survival after liver retransplantation for late graft failure based on preoperative prognostic scores. Hepatology 39 (2004) 230-238
141. Watt K.D.S., Lyden E.R., and McCashland T.M. Poor survival after liver transplantation: is hepatitis C to blame?. Liver Transpl 9 (2003) 1019-1024
142. Burton J.R., and Rosen H.R. Liver retransplantation for hepatitis C virus recurrence: a survey of liver transplant programs in the United States. Clin Gastroenterol Hepatol 3 (2005) 700-704
143. Rosen H.R. Retransplantation for hepatitis C: implication of different policies. Liver Transpl 6 Suppl (2000) S41-S46
144. Burton J.R., Sonnenberg A., and Rosen H.R. Retransplantation for recurrent hepatitis C in the MELD era: maximizing utility. Liver Transpl 10 (2004) S59-S64
145. Edwards E., and Harper A. Does MELD work for relisted patients?. Liver Transpl 10 (2004) S10-S16
146. Kremers W.K., van Ijperen M., Kim W.R., et al. MELD score as a predictor of pretransplant and posttransplant survival in OPTN/UNOS status 1 patients. Hepatology 39 (2004) 764-769
147. United Network for Organ Sharing. Policy 3.6, organ distribution: allocation of livers. Available at: http://www.unos.org/PoliciesandBylaws/policies/pdfs/policy_8.pdf.
148. Stange B.J., Glanemann M., Nuessler N., et al. Hepatic artery thrombosis after adult liver transplantation. Liver Transpl 9 (2003) 612-620